Introduction, results and discussion
Ornithine transcarbamylase (OTC) deficiency, an X-linked recessive condition, is the most common of the urea cycle disorders. 1 Mutations in the OTC gene range from deletions and insertions to point mutations that affect either protein activity and/or stability. 2 Undetectable enzyme activity causes severe neonatal hyperammonemia and is associated with a high risk of coma and death, and significant morbidity in those surviving the newborn period. Patients with as little as 3% normal enzyme activity have a mild or late presenting phenotype more readily managed with contemporary therapy. 2 Thus, for patients with the severe neonatal form, even relatively low levels of gene correction are likely to confer significant therapeutic benefit. One possible limitation of gene therapy in this setting, however, is the patient's mutant enzyme exerting a dominant-negative effect on vector-encoded wild-type OTC. Evidence for this phenomenon has been reported in vitro. 3 The OTC protein is predominantly expressed in the liver and intestinal mucosa as an inactive precursor polypeptide containing an N-terminal leader sequence. On transport to the mitochondria the leader sequence is cleaved and the protein assembled into an active homotrimeric form that catalyses conversion of ornithine and carbamyl phosphate to citrulline and inorganic phosphate. 4 In OTC deficiency, accumulation of carbamyl phosphate leads to orotic aciduria, a useful biochemical marker of this disease.
Recombinant adeno-associated virus (rAAV) vectors are capable of achieving high-level gene transfer to the mouse liver and, therefore, show significant promise for the treatment of metabolic liver diseases. 5 In the spf ash mouse model of OTC deficiency, our group has shown liver-wide murine OTC expression after rAAV2/8-mediated delivery. 6 At a vector dose of 1.5 Â 10 12 vector genomes (vg) per mouse, OTC enzyme activities over an order of magnitude above physiological levels were observed, with complete biochemical correction achieved at a substantially lower dose of 1.5 Â 10 11 vg per mouse. These unprecedented levels of wild-type OTC expression achieved in adult mouse livers with a rAAV2/8-based vector provided an opportunity to determine whether mutations in the OTC gene can exert dominant-negative effects in vivo. We selected three clinicallyrelevant mutations that have been shown to be essential for substrate binding, and hence enzymatic activity, while retaining normal levels of protein expression and stability. The first of these mutations was a single base pair substitution (CGA to CAA) that changes the arginine residue at codon 92 to glutamine (R92Q). In humans, expression of this point mutation results in a severe neonatal phenotype. 7 Studies by other researchers have shown that co-expression of both wild-type and mutant OTC substantially inhibited wild-type enzyme activity, suggesting the R92Q mutation exerts a dominant-negative effect, at least in vitro. 3 The next two mutations result in amino acid substitutions R141Q or K88N and produce a severe neonatal 8 or late presenting phenotype, 9 respectively. Mutation R141Q affects the carbamyl phosphate-binding site without altering the tertiary structure of the protein 10 whereas K88N alters a lysine residue in the substrate-binding site of OTC.
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Based on theoretical considerations, heterotrimeric enzyme containing these mutant and wild-type subunits might be expected to exhibit impaired catalytic function. For the R141Q mutation in vitro analyses have not detected a dominant-negative effect, 8 whereas the possible effect of the K88N mutation has yet to be examined. To date no OTC mutations have been investigated in vivo.
Groups of wild-type adult male mice received one of the three mutant OTC-encoding rAAV2/8 vectors (Figure 1) . Vector was delivered to the liver by i.p. injection of 1 Â 10 12 vg per mouse, a dose shown earlier by our group to produce liver-wide gene transfer 12 and induction of super-physiological OTC protein levels. 6 Base-line and weekly urinary orotic acid levels were determined and compared with values obtained for control mice that received either wild-type OTC-encoding vector or phosphate buffered saline (PBS). Six weeks later the mice were killed and the livers harvested. This period of time was chosen to allow sufficient time for both turnover of endogenous wild-type OTC, having a halflife of 6-9 days, 13 and formation of heteromeric OTC trimers with mixed wild-type and mutant subunits. Analysis of urinary orotic acid levels showed no difference between mice expressing mutant OTC proteins compared with controls at any of the time points examined (Figure 2 ). The level of urinary orotic acid in affected adult mice is significantly higher at 629 ± 70 mmol orotate per mmol creatinine (n ¼ 8). 6 This implies that these mutant proteins do not exert a phenotypically significant dominant-negative effect on wild-type OTC.
To confirm that these vectors encoded stable but functionally defective OTC proteins, western analysis was carried out on whole-cell liver lysates. In mice injected with either the wild-type or mutant vectors, between approximately 5 and 23-fold over-expression of OTC was observed in comparison with results obtained from PBS-injected control animals ( Figure 3 ). Importantly, this confirmed that the vectors encoded stable OTC proteins that were successfully targeted to the liver. Consistent with our earlier findings, 6 the mutant OTC expression levels achieved were markedly in excess of endogenous physiological wild-type OTC levels.
We next examined whether the presence of mutant protein, with the potential to form heteromeric OTC trimers with mixed wild-type and mutant subunits, reduced enzymatic activity in vivo. In mice treated with 0 -GACAGATGCAGT GTTAGCTCAAGTGTATAAACAATCAGATCTGG-3 0 and 5 0 -CCA GATCTGATTGTTTATACACTTGAGCTAACACTGCATCTGTC-3 0 . Underlining indicates the base pairs mismatched with wild-type murine OTC sequence (GenBank accession number BC024893). The DNA sequences of mutant OTC genes were confirmed to ensure that no spurious mutations had been introduced. Mutant OTC genes were sub-cloned into the Eco RI and Eco RV restriction endonuclease sites of pLSP1-mOTC 6 to replace the wild-type transgene. Figure 2 Level of urinary orotic acid after liver-directed gene delivery. Base-line urinary orotic acid levels were determined 6 and adult mice (8-10 week) subsequently injected with 1 Â 10 12 vector genomes through the intraperitoneal route. Urinary orotic acid levels were determined weekly for 6 weeks post-injection. D, PBS control; m, wild-type OTC; ', K88N-encoding vector; Â , R92Q-encoding vector;~, R141Q-encoding vector. Values represent mean ± s.e.m. for each time point (n ¼ 4 for mutant vectors and n ¼ 5 for wild-type and PBS-injected controls, respectively) with a mean urinary orotic acid value for affected mice being 629±70 mmol orotate per mmol creatine (n ¼ 8). The local institutional Animal Care and Ethics Committee approved all animal experiments. Vectors expressing wild-type or mutant OTC proteins were packaged with a helper virus-free system 14 into rAAV8 capsids using the DNA calcium-phosphate co-precipitation technique 15 as described earlier. 12 Vector was purified through two CsCl gradients, dialysed against PBS (containing calcium and magnesium) and the titre (vector genomes per ml) determined by quantitative PCR. 12 OTC mutant analysis for dominant-negative affects SL Ginn et al vectors expressing the K88N, R92Q or R141Q mutations, wild-type OTC activity was unaffected despite the high vector dose used (Figure 4) . In contrast, administration of vector encoding wild-type OTC increased enzyme activity to approximately 5-fold above wild-type levels (Figure 4) . Collectively, these results indicate that the mutations examined do not exert dominant-negative effects on wild-type OTC in vivo even when in significant excess.
Upto the present time, studies investigating the effects of mutant proteins on wild-type OTC function have used in vitro models and, in an earlier study, the R92Q mutation has been proposed to exert a dominantnegative effect. 3 In this earlier study, human hepatocytes established from a patient carrying the R92Q mutation were transduced with an adenoviral vector expressing wild-type OTC and the levels of activity compared with another patient-derived line, transduced with the same vector. The authors found that enzyme activity did not correlate with protein levels and proposed a dominantnegative effect for the R92Q mutation. In contrast, our in vivo study shows that the presence of the R92Q mutant does not affect either orotic acid levels or OTC activity. To date, the R92Q mutation is the only allele suggested to exert a dominant-negative effect, although in vitro, making it the obvious positive control to include in our study. In our hands, however, a dominant-negative effect was not observed. Although the reason for this discrepancy is unclear, it is likely to reflect inherent differences between the in vitro and in vivo models used. In addition, the relative permissiveness of the two patient-derived lines for the adenoviral vector and the levels of transduction achieved were not established quantitatively. Importantly, our system more closely replicates a clinical setting where it would be expected that the amount of endogenous mutant protein would exceed the functional OTC introduced by gene transfer.
In summary, the ability to achieve markedly supraphysiological levels of OTC expression in adult mouse livers with a rAAV2/8-based vector has facilitated the demonstration of a lack of dominant-negative effects for three clinically-relevant OTC mutations (K88N, R92Q and R141Q). After liver-targeted delivery of rAAV2/8 vectors encoding mutant OTC, no increase in urinary orotic acid levels or reduced OTC enzyme activity was observed in vivo. Our data has important implications for the development of human clinical trials for the treatment of OTC deficiency and provides a model system in which the effects of specific mutations on OTC function can be examined empirically before gene therapy. Finally, the lack of dominant-negative effects observed in vivo, at least for these three mutations, is favorable for the development of human clinical trials for OTC deficiency where both mutant and wild-type proteins would be expressed within the same cell. Figure 3 Western blot analysis of mutant OTC protein expression in rAAV2/8-transduced livers. Mice were killed at 6 weeks postinjection and the livers harvested. Western blot analysis was subsequently carried out on 15 mg of protein as described earlier. 6 After gene delivery, protein levels were found to be 9.9-(wild-type), 5.3-(K88N), 9.1-(R92Q) and 23.3-(R141Q) fold higher than the level observed in PBS-injected controls. Liver lysates were prepared by sonication (Ultra Turrax -T25 basic, IKA Labortechnik, Staufen, Germany) in lysis buffer (0.5% (v/v) TritonX-100, 10 mM HEPES pH 7.4 and 2 mM DTT) containing protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) followed by three freeze/thaw cycles and clearing by centrifugation (12,000 g for 10 min at 4 1C). Lysate protein concentrations were determined using the DC Protein Assay (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. After transfer to nitrocellulose (Bio-Rad), blots were probed with primary rabbit polyclonal antibody to OTC (1:1000 dilution). A secondary goat anti-rabbit-HRP conjugate (1:25,000 dilution; Bio-Rad) in conjunction with SuperSignal West Pico Chemiluminescent substrate (Pierce, Rockford, IL, USA) was used for detection (top panel). The membrane was stripped using 0.2 M NaOH and re-probed with rabbit anti-actin antibody (1:500 dilution; Sigma-Aldrich, St Louis, MO, USA) as a loading control (bottom panel). The level of OTC protein was standardized against actin using a GS-800 calibrated densitometer (Bio-Rad) running Quantity One software (version 4.2.2). Figure 4 Ornithine transcarbamylase (OTC) activities in liver lysates after gene delivery of wild-type and mutant proteins. Mice were killed at 6 weeks post-injection and the livers harvested. Whole-cell lysates were prepared (Figure 3 ) and the OTC enzymatic activity determined. 16 Values are expressed as mmol citrulline per mg protein per hour and represent mean ± s.e.m. for each treatment group (n ¼ 4 for mutant vectors and n ¼ 5 for wild-type and PBSinjected controls, respectively).
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